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Shailendra K Saxena4, Patricia Diaz1,2, Semithe Chevelon1,2, Michael Concepcion1 and Madhavan Nair1,2,3*
Abstract
Background: Although highly active antiretroviral therapy (HAART) has significantly reduced the morbidity and
mortality in HIV patients, virus continues to reside in the central nervous system (CNS) reservoir. Hence, a complete
eradication of virus remains a challenge. HIV productively infects microglia/macrophages, but astrocytes are
generally restricted to HIV infection. The relative importance of the possible replication blocks in astrocytes,
however, is yet to be delineated. A recently identified restriction factor, sterile alpha motif and histidine/aspartic
acid domain-containing protein 1 (SAMHD1), restricts HIV infection in resting CD4+T cells and in monocyte-derived
dendritic cells. However, SAMHD1 expression and HIV-1 restriction activity regulation in the CNS cells are unknown.
Though, certain miRNAs have been implicated in HIV restriction in resting CD4+T cells, their role in the CNS HIV restriction
and their mode of action are not established. We hypothesized that varying SAMHD1 expression would lead to restricted
HIV infection and host miRNAs would regulate SAMHD1 expression in astrocytes.
Results: We found increased SAMHD1 expression and decreased miRNA expression (miR-181a and miR-155) in
the astrocytes compared to microglia. We report for the first time that miR-155 and miR-181a regulated the
SAMHD1 expression. Overexpression of these cellular miRNAs increased viral replication in the astrocytes, through
SAMHD1 modulation. Reactivation of HIV replication was accompanied by decrease in SAMHD1 expression.
Conclusions: Here, we provide a proof of concept that increased SAMHD1 in human astrocytes is in part
responsible for the HIV restriction, silencing of which relieves this restriction. At this time, this concept is of
theoretical nature. Further experiments are needed to confirm if HIV replication can be reactivated in the CNS
reservoir.
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Introduction
HIV-1 infection of astrocytes results in an initial productive,
non-cytopathogenic infection that diminishes to a poorly
productive, persistent infection [1,2]. Even though astrocyte
infection is ‘restricted,’ their infection results in cellular
dysfunction, contributing to the development of
HIV-associated neurocognitive disorders (HAND) [3].
Though astrocytes lack surface CD4 receptor, astrocytes
get infected by a CD4-independent viral entry, through
the mannose receptor that is expressed on the surface of
astrocytes [4-6]. Infected astrocytes initiate productive
infection of HIV-permissive blood-derived cells in co-
culture experiments [7,8]. Although potent highly ac-
tive antiretroviral therapy (HAART) suppresses plasma
viremia to undetectable levels [9], it is unable to eliminate
the virus from quiescent reservoirs [10-12] and/or from
sanctuaries like the brain [13-15]. The astrocytic reservoir
protected from HAART is capable of initiating new
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infections upon treatment discontinuation and constitutes
an important hindrance to HIV clearance from the central
nervous system (CNS) [7,16,17].
Deciphering the innate molecular mechanisms that re-
strict HIV replication and establish persistent reservoirs
is essential for developing strategies to reactivate the res-
ervoir. Overcoming the blocks in HIV replication can
lead to the upregulation of the gene expression, making
these cells available to immune surveillance and HAART
targeting. Efficient replication is blocked in astrocytes at
different steps of the HIV life cycle [1,8,18]. Although
several pre-transcriptional and post-transcriptional
mechanisms are shown to contribute to HIV latency,
whether SAMHD1 contributes to the viral restriction in
astrocytes is not known [19,20].
Specific ‘intrinsic host restriction’ factors restrict virus
replication in mammalian cells. Some cells constitutively
express these factors, and in others, they are induced by
interferons as part of the innate immune response. Apo-
lipoprotein B mRNA-editing enzyme 3G (APOBEC-3G)
[21], bone marrow stromal cell antigen 2 (BST-2) [22],
tripartite motif protein 5 alpha (TRIM-5α) [23], and cel-
lular miRNAs [24] are examples of restriction factors
targeting HIV-1. SAMHD1, a recently identified nuclear
protein restriction factor, hydrolyzes cellular deoxynu-
cleotide (dNTP) pools and hampers retrovirus reverse
transcription [25]. Due to the limited deoxynucleotide
substrate availability, SAMHD1 inhibits HIV infection of
myeloid cells and naïve CD4+T cells [26,27]. However,
SAMHD1-mediated restriction has not been explored in
CNS cells. We hypothesized that increased expression of
SAMHD1 restricts HIV infection in astrocytes. In this
study, we compared the expression of SAMHD1 in as-
trocytes and microglia and correlated with the HIV
replication.
Some studies have shown that SAMHD1 phosphoryl-
ation status correlates with the restriction activity but
not its dNTPase activity [28]. However, little is known
about the post-transcriptional regulation of SAMHD1
expression. MicroRNAs have been implicated in the
HIV gene expression and latency in CD4+T cells [29-31].
It is not known whether miRNA modulation plays a role
in HIV-1 restriction in astrocytes, and whether miRNA
regulates SAMHD1 gene expression. Hence, in this re-
port, we also examined SAMHD1 regulation by miRNA.
Here, we report that astrocytes display higher SAMHD1
expression compared to microglia, which is in part ac-
countable for HIV restriction in the astrocytes and miR-
181a regulates SAMHD1.
Results
HIV infection in astrocytes is restricted
To better understand the mechanism behind HIV re-
striction in astrocytes, we infected astrocytes and
microglia with HIV-1Bal (100 ng p24) and estimated the
viral replication (by measuring p24 Ag level) in the culture
supernatant at 3, 5, 7, 10, 15, and 20 days post infection
(dpi). HIV-1 infection in astrocytes peaked at day 5
(450 pg/ml), which then diminished at day 7 and remained
low from day 10 onwards (Figure 1A). Whereas, com-
pared to astrocytes, microglia had significantly higher p24
level at day 5 (2,000 vs 450 pg/ml) (Figure 1A), which fur-
ther increased and remained high till 20 dpi. Our observa-
tion is in agreement with previous reports, which showed
that HIV-1 infection of astrocytes results in an initial pro-
ductive, non-cytopathogenic infection that diminishes to a
poorly productive, persistent infection leading to a latent
state [1,2,32]. We also conducted the infection using pseu-
dotyped virus. A lentiviral packaging system was used to
generate vesicular stomatitis virus (VSV)g Env-pseudotyped
viral particles that contained a HIV-1-integrating provirus
(devoid of Env and encoding a luciferase reporter). VSV-G
pseudotyped virus can enter CD4 negative cells and thus
circumvent the entry restriction in cells lacking CD4 recep-
tors. Compared to microglia, astrocytes have less relative
light units (RLU) (Figure 1B) suggesting that even if the
entry restriction is bypassed, there are post-entry blocks to
HIV infection in astrocytes.
Astrocytes display higher SAMHD1 expression
Though SAMHD1 has been shown to be responsible for
the non-susceptibility of myeloid cells, resting CD4 T
cells and macrophages to HIV infection [26,27], its ex-
pression has not been evaluated in CNS cells yet. Here,
we compared the expression of SAMHD1 in two pri-
mary CNS cell types (astrocytes and microglia), which
are differentially infected by HIV. We performed real-
time PCR analysis to quantify SAMHD1 mRNA expression.
By comparing SAMHD1 expression in these two cell types,
we expected to see a differential expression of SAMHD1 in
non-productively (astrocytes) and productively (microglia)
infected cells. As expected, we found that constitutive
expression of SAMHD1 mRNA was sevenfold higher in
astrocytes compared to microglia (Figure 1C). To further
confirm, if the gene expression observed corresponds to
protein expression, we performed immunoblotting to
detect SAMHD1 protein levels. Similar to gene expression
pattern, astrocytes displayed increased SAMHD1 protein
expression (Figure 1D). This was further confirmed by
intra cellular expression by flow cytometry (Figure 1E).
HIV replication kinetics correlates with SAMHD1
expression
SAMHD1 hydrolyzes dNTPs and lowers their concen-
trations to a level that is suboptimal for reverse tran-
scription of viral RNA [25]. We asked whether the
SAMHD1 expression plays a role in the restriction of
HIV replication in astrocytes and examined whether
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SAMHD1 expression is modulated by HIV infection. Re-
verse transcriptase activity measurement was done in
culture supernatant at 3, 5, 7, 10, 15, and 20 dpi. The re-
verse transcriptase assay estimates the quantitative deter-
mination of reverse transcriptase (RT) activity. Consistent
with p24 level, we found higher reverse transcriptase ac-
tivity in astrocytes at day 5 post infection, which decreased
thereafter (Figure 1F). Reverse transcriptase activity was
significantly higher in microglia compared to astrocytes at
all-time points (Figure 1F). This suggests that low reverse
transcriptase activity contributes towards the restriction of
HIV infection observed in astrocytes. Subsequently, we
analyzed SAMHD1 mRNA expression in the cells at these
same time points following infection and compared with
baseline. SAMHD1 mRNA expression in astrocytes was
higher at 3 dpi compared to baseline. At day 5, SAMHD1
Figure 1 Restricted HIV replication kinetics correlates with SAMHD1 expression. (A) 1 × 106 cells/ml astrocytes and microglia were infected
with HIV-1BAL (100 ng p24) for overnight, washed and replenished with fresh medium. Virus replication kinetics is quantitated in cell culture supernatant
over a 20-day time course, by the production of p24 antigen. (B) Cells were infected with the HIV-luciferase pseudovirus (20 ng) for 3 days, harvested,
washed with PBS and lysed. Luciferase concentration in whole cell lysates was determined. (C) RT-PCR based quantification of SAMHD1 mRNA levels. Total
cellular RNA was extracted from microglia and astrocytes (infected with HIV-1BAL) and amplified by specific primer for SAMHD1 gene expression. All data
was normalized to GAPDH. Data shown represents fold change in mRNA levels. (D) SAMHD1 protein expression was detected by immunoblotting with
SAMHD1-specific antibodies in corresponding cell lysates. Equal amounts of total protein (30 μg) of the lysates from both cells were loaded. GAPDH was
used as a loading control. (E) Intracellular SAMHD1 expression of microglia and astrocytes. Cells (1 × 106) were immunostained by FITC-conjugated SAMHD1
monoclonal Ab and analyzed by flow cytometry. Percentage of cells expressing SAMHD1 is indicated. (F) Cell culture supernatant from astrocytes and
microglia after HIV infection was assessed for viral reverse transcriptase activity over 20 days by colorimetry. (G) Total cellular RNA was extracted from the
corresponding cells following HIV infection (over a 20-day time course) and SAMHD1 mRNA levels quantitated by RT-PCR. (H) SAMHD1 protein expression
was detected by immunoblotting with SAMHD1-specific antibodies in corresponding cell lysates at 3, 5, 7, 10, and 15 days following HIV infection. Results
shown are mean ± SEM of three independent experiments for A, B, C, F, and G. P value ≤0.05 were considered to be significant. SAMHD1, sterile alpha
motif and histidine/aspartic acid domain-containing protein 1; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; RT, reverse transcriptase; RLU, relative
light units.
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expression was decreased, which further increased on day 7
and remained high thereafter (Figure 1G). Interestingly, in
astrocytes, SAMHD1 gene expression was lowest at day 5,
when the p24 level was the highest. SAMHD1 protein ex-
pression was also lower on day 5 (Figure 1H). Even though
microglia did not show much significant change in the
SAMHD1 mRNA expression during the course of infection,
the increase in SAMHD1 protein expression was more prom-
inent than gene expression during HIV infection (Figure 1H).
SAMHD1 silencing relieves the ‘restriction’
To further confirm the role of SAMHD1 in the astrocytic re-
striction, we evaluated whether SAMHD1 modulation is suf-
ficient to change the viral replication. We transfected the
astrocytes (0.5 × 106) with SAMHD1 siRNA (70 nm) to
silence SAMHD1 expression, followed by HIV infection. The
efficiency of siRNA-mediated silencing was confirmed by
strong inhibition of SAMHD1 protein as determined by
Western blot analysis (Figure 2A). When we estimated p24
level in the culture supernatant after 72 h post infection, we
found significantly higher HIV replication with SAMHD1
silencing (p24 Ag production increased from 390 ± 37.86 to
1,383 ± 169.1 pg/ml) compared to mock transfected cells
(Figure 2B). Transfection with negative control siRNA
(which consists of a scrambled sequence that will not lead
to the specific degradation of the target) did not have any
change in infection in astrocytes. This result substantiates
that depletion of cellular SAMHD1 in astrocytes is sufficient
to alleviate the restriction to HIV infection.
In order see if the SAMHD1-mediated repression of
HIV-1 replication is due to its ability to repress reverse
transcription, we evaluated whether the process of reverse
Figure 2 SAMHD1 silencing promotes HIV replication in astrocytes. (A) Astrocytes (2 × 105 cells/ml) were transfected with 75 pmols
SAMHD1-specific siRNA using Lipofectamine 2000. SAMHD1-knockdown was assessed by immunoblotting with SAMHD1-specific antibodies. One
representative blot is shown. (B) SAMHD1-siRNA or control siRNA transfected astrocytes were infected by HIV (100 ng p24). Cells were treated
with or without 100 nm AZTTP. After 72 h, p24 was measured in supernatants by ELISA. (C) Total RNA was extracted from corresponding cells
from ‘B’ and amplified by RT-PCR for HIV-1 LTR/RU-5 gene. (D) SAMHD1- siRNA transfected astrocytes were infected with the HIV-luciferase pseudovirus
(20 ng) for 3 days, harvested and lysed. Luciferase concentration in whole cell lysates was determined. (E) Astrocytes were treated with or
without raltegravir (10 μM) for 6 h followed by TSA (50 nM) treatment. Cells were infected with the HIV-luciferase pseudovirus (20 ng) for
3 days. Luciferase concentration in whole cell lysates was determined. (F) Astrocytes (1 × 106 cells/ml) were treated with trichostatin A (TSA; 50
nM) for 24 h or left untreated. Following the treatment, SAMHD1 mRNA levels were quantified by real-time PCR analysis. The SAMHD1 mRNA
level in cells without TSA was set to 1. P value ≤0.05 were considered to be significant. (G) Cell lysate was prepared from the corresponding
cells in (F), and SAMHD1 protein expression was detected in corresponding cell lysates by immunoblotting with SAMHD1-specific antibodies.
Equal amounts of total protein (30 μg) from both cells were loaded. GAPDH was used as a loading control. Results shown are representative
of mean ± SEM of three independent of experiments (except A and G). P value ≤0.05 were considered to be significant. SAMHD1, sterile alpha
motif and histidine/aspartic acid domain-containing protein 1; LTR, long terminal repeat; AZTTP, azidothymidine triphosphate; TSA, trichostatin
A; VSV-G, vesicular stomatitis virus; RLU, relative light units; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
Pilakka-Kanthikeel et al. Journal of Neuroinflammation  (2015) 12:66 Page 4 of 12
transcription occurred efficiently following SAMHD1 si-
lencing. Infected astrocytes were analyzed by qPCR for
early reverse transcription products at 72 h post infection
using a set of primers specific for long terminal repeat
(LTR) R/U5 (short first transcript). Sequences of PCR
primers have been previously described [33]. We saw that
SAMHD1 inhibition increased LTR R/U5 approximately
2.5-fold (Figure 2C). Negative control siRNA transfection
did not show any difference in the LTR R/U5 expression.
These results indicate that SAMHD1 has an effect at the
reverse transcription phase in astrocytes. Interestingly,
SAMHD1 silencing did not show any significant change
in the p24 in microglia (not shown).
We treated the astrocytes with a reverse-transcriptase
inhibitor, azidothymidine triphosphate (AZTTP, 100 nm)
6 h before siRNA transfection. Treatment with AZTTP
significantly inhibited the p24 production in infected
astrocytes (390 ± 37.86 to 30.67 ± 3.48, 93% decrease;
Figure 2B). SAMHD1 siRNA-mediated increase in the
p24 level was also inhibited by AZTTP (1,383 ± 169.1
to 250.3 ± 28.87 pg/ml, 82% decrease). Similar to the
observation in p24 level, AZTTP treatment suppressed
SAMHD1 siRNA-mediated increase in LTR R/U5 ex-
pression (Figure 2C). Further, we infected the astrocytes
with VSV-G pseudotype virus following SAMHD1
siRNA transfection. We found approximately two fold
increase in luciferase activity after SAMHD1 siRNA
transfection (Figure 2D). This further confirms that
SAMHD1 has a role in suppression of HIV-1 replica-
tion in astrocytes, even though the virus gets rid of the
entry restriction. This is in accordance with the previ-
ous reports in resting CD4 T cells and myeloid cells
explaining that SAMHD1 is responsible for the efficient
reverse transcription [27,34,35]. These results confirm
the role of SAMHD1 as a restriction factor that facili-
tates in HIV-1 restriction in astrocytes and silencing
SAMHD1 relieves the ‘restriction.’ Additional investiga-
tions are needed to confirm that the restriction is at the
level of reverse transcription. However, the possibility
of additional SAMHD1-dependent/independent mecha-
nisms cannot be excluded.
Reactivation decreases SAMHD1 expression
Neutralizing the miRNAs or histone deacetylase (HDAC)
inhibitors treatment in latently infected cells has shown to
revert the latency and reactivate the HIV infection
[36-38]. We wanted to see if the reactivation of virus is ac-
companied by change in SAMHD1 expression. An in vitro
model mimicking latent infection in astrocyte was pre-
pared as described by Gray et al. to make sure the cells
were in latent stage before trichostatin A (TSA) treatment
[39]. Astrocytes were infected with the pseudotyped virus
in the presence or absence of the integrase inhibitor ralte-
gravir for 2 days. Cells were then treated with TSA and
reactivation from latency was assessed by measuring lucif-
erase activity. As shown in Figure 2E, TSA treatment in-
duced reactivation from raltegravir-treated cells. This was
in agreement with the abovementioned reports, which
showed an increase in HIV replication with TSA treat-
ment. We further evaluated the SAMHD1 expression in
TSA treated cells. We found that TSA treatment was ac-
companied by a decrease in the SAMHD1 expression both
in gene and protein level (Figure 2F, G).
miR-181a and −155 targets SAMHD1 in astrocytes
Neutralizing the miRNAs in latently infected cells has
shown to revert the latency [38]. Yet, the information
available about role of miRNAs in CNS HIV replication
is limited. Moreover, mechanism of SAMHD1 regulation
is also not known. Since both miRNAs and SAMHD1
plays a role in HIV replication, we asked whether
SAMHD1-mediated HIV-1 restriction in astrocytes is
regulated by miRNA-mediated translational inhibition.
We screened web-based tools TargetScan (http://www.
targetscan.org/) and http://www.mirdb.org to identify
potential miRNAs that can target SAMHD1 (by searching
for the presence of conserved 8mer and 7mer sites that
match the seed region of each miRNA). We were able to
identity few miRNAs (miR-124, −150, −155, −181a-d, −490,
and −496) that have binding sites on SAMHD1. We con-
centrated our further experiments on miR-155 and -181a,
because of their importance in the brain and latency
[40-43].
To verify the relatively abundant expression of these
two miRNAs, we measured constitutive expression of
miR-181a/-155 in astrocytes and microglia by TaqMan
assay (Life Technologies, Carlsbad, CA, USA). We saw
significantly lower constitutive expression of miR-181a
and miR-155 in astrocytes (in which SAMHD1 expres-
sion is higher) compared to microglia (Figure 3A). The
level of both miRNAs was comparable in astrocytes.
Our next aim was to assess the inhibitory effects of miR-
181a and miR-155 on SAMHD1 expression and to verify
that the SAMHD1 is a direct target of these identified
miRNA sequences. We transfected astrocytes with spe-
cific miR-181a or miR-155 inhibitor/mimic (Ambion) for
72 h using Lipofectamine (Invitrogen, Carlsbad, CA,
USA) and analyzed the SAMHD1 expression. miR-146a,
a non-targeting miRNA, was used as control. qPCR ana-
lysis revealed an increase in SAMHD1 mRNA expres-
sion with miR-155 (2.6-fold) and miR-181a inhibition
(3.4-fold), compared to non-transfected cells, miR-181a
being more effective (Figure 3B). Although individual in-
hibitors increased SAMHD1 only modestly, the combin-
ation of these two miRNA inhibitors resulted in a
substantial increase in SAMHD1 expression (sixfold
higher than the control) in astrocytes (Figure 3C). On the
other hand, over expression of miR-181a and miR-155 by
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respective mimics suppressed the SAMHD1 mRNA ex-
pression in astrocytes (Figure 3B). Non-targeting miRNA
(miR-146a) mimic/inhibitor did not have any effect on
SAMHD1 expression. Given the significant induction of
SAMHD1 mRNA in astrocytes with miRNA inhibition,
immunoblotting was performed to examine whether the
increase in SAMHD1 mRNA resulted in the expression of
SAMHD1 protein. SAMHD1 protein was also induced
with miR-181a inhibition compared to untreated control
(Figure 3D). miR-181a inhibitor increased the luciferase
activity in VSV-G pseudotype virus infection and miR-
181a mimic transfection decreased the luciferase activity
(Figure 3E). These results illustrate that transfection with
miR-181a/miR-155 inhibitor and mimic modulated the
SAMHD1 expression confirming that SAMHD1 is regu-
lated by miR-181a and miR-155.
miR-181a/miR-155 inhibition increases HIV replication
Further, we wanted to verify that the identified putative
miRNAs have roles in the suppression of HIV-1 protein
expression. We transfected astrocytes with miRNA
mimic/inhibitor as described above and cultured with
HIV for 72 h. p24 production was measured in the culture
supernatants. We found that miR-181a and miR-155 over-
expression displayed an increase in p24, whereas their in-
hibition resulted in p24 reduction (Figure 4A). Over
expression of non-targeting miRNA (miR-146a) did not
have any significant change on p24 level. Interestingly,
Figure 3 miR-155 and -181a target SAMHD1. (A) Quantification of miRNA levels. Total cellular microRNA was extracted from microglia and
astrocytes and amplified for miRNA expression by qRT-PCR using specific primer for miR-155 and miR-181a. miRNA levels were normalized to U6
snRNA control and the cycle threshold (Ct) values were calculated. (B) Astrocytes (2 × 105 cells/ml) were transiently transfected with mimic or
inhibitor for miR-155, miR-181a, and miR-146a, at a final concentration of 50 nmol. After 72 h, total cellular RNA was extracted and amplified
by specific primer for SAMHD1 gene expression by RT-PCR. All data was normalized to GAPDH. Data shown represents fold change in mRNA
levels. (C) Astrocytes (2 × 105 cells/ml) were transiently transfected with inhibitor for miR-155, miR-181a, or miR-146a individually or a
combined transfection with both miR-155 and miR-181a inhibitors. Following transfection, SAMHD1 mRNA levels were quantified by
RT-PCR. (D) Lysates were prepared from miR-181a inhibitor transfected cells and SAMHD1 protein expression was detected in corresponding
cell lysates by immunoblotting with SAMHD1-specific antibodies. Equal amounts of total protein (30 μg) of the lysates from both cells were
loaded. GAPDH was used as a loading control. (E) Astrocytes (2 × 105 cells/ml) were transiently transfected miR-181a inhibitor/mimic at a final
concentration of 50 nmol. After 12 h, cells were infected with the HIV-luciferase pseudovirus (20 ng). At day 3, cells were harvested, washed
with PBS, and lysed. Luciferase concentration in whole cell lysates was determined. Results shown are representative of mean ± SEM of three
independent experiments (except for (D)). P value ≤0.05 were considered to be significant. SAMHD1, sterile alpha motif and histidine/aspartic
acid domain-containing protein 1; VSV-G, vesicular stomatitis virus; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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miR146a inhibition resulted in a slight increase. Reduction
in p24 by reverse-transcriptase inhibitor (AZTTP)
treatment was abrogated by miR-181a overexpression
(Figure 4B). Our data indicated that overexpression of
these two miRNAs by their corresponding mimics in-
creases HIV-1 production from astrocytes, suggesting
that miRNA overexpression alleviates the restriction.
Further investigations are necessary to confirm whether
these miRNA can reactivate productive infection in the
astrocytes.
Further, we wished to determine whether miRNA(s)
have a direct role in the regulation of HIV-1 gene ex-
pression or whether the miRNA-mediated regulation of
HIV-1 replication is through its ability to modulate
SAMHD1. We co-transfected SAMHD1 siRNA and
miR-181a inhibitor in astrocytes, followed by HIV infec-
tion. As shown in previous experiment, SAMHD1 silen-
cing increased the p24 level, whereas miR-181a
inhibition decreased p24 level (Figure 4C). Interestingly,
co-transfection did not have significant change in p24
level compared to the untreated control. This data con-
firms that miR-181a/miR-155-mediated HIV regulation
is by inhibiting SAMHD1.
Discussion
Astrocytes, which constitute 40% to 70% of total cells in
the CNS [1], perform key regulatory functions critical to
brain function. The different CNS cell types are differen-
tially infected with HIV; microglia being highly suscep-
tible, astrocytes moderately restrictive, and neurons
highly restrictive. Despite the lack of CD4 receptors, as-
trocytes become infected via CD4-independent mechan-
ism [6,44]. In line with the earlier studies [1,2], we also
found low level of HIV replication in astrocytes com-
pared to microglia. After the initial productive phase, in-
fection subsides to a persistent stage in astrocytes, which
goes in hand with reports from other investigators
[1,2,32]. Infected astrocytes produce very low levels of
virus even in the acute phase in contrast to infection of
T-lymphocytes [45,46]. Our results with pseudotyped
Figure 4 miR-155/-181a inhibition increases HIV replication. (A) Astrocytes (2 × 105 cells/ml) were transiently transfected with mimic or inhibitor
for miR-155, miR-181a, and miR-146a, at a final concentration of 50 nmol, followed by HIV infection. After 72 h, supernatants were collected and assayed
for p24 by ELISA. (B) Astrocytes (2 × 105 cells/ml) were transiently transfected with miR-181a mimic, followed by infection with HIV-1BAL (100 ng p24)
with or without 100 nm AZTTP. p24 level was measured in the supernatant from astrocytes cultures. (C) Astrocytes (2 × 105 cells/ml) were transiently
transfected with SAMHD1 siRNA (75 pmols) and miR-181a inhibitor (50 nmols) individually or a combined transfection with both. After 72 h, supernatants
were collected and assayed for p24 by ELISA. Results shown are representative of mean ± SEM of three independent experiments. P value ≤0.05 were
considered to be significant. SAMHD1, sterile alpha motif and histidine/aspartic acid domain-containing protein 1; AZTTP, azidothymidine triphosphate.
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virus confirm that regardless of the entry routes, there
are post-entry blocks to infection in astrocytes. Though
the introduction of potent HAART has significantly
controlled the viral replication in HIV patients, the
current antiviral strategies target only actively replicat-
ing virus. Having said that, persistently infected brain
astrocytes would not be susceptible to antiviral drugs,
allowing the virus to persist in these reservoirs. Hence,
the complete eradication of the virus from the host re-
mains an impossible task. Several post-transcriptional
and post-translational mechanisms [19,20], a number of
host restriction factors [21,22], and certain cellular
miRNAs [24] have been reported to hinder retroviral
replication in astrocytes contributing to HIV latency.
SAMHD1, a recently identified nuclear protein restriction
factor, is highly expressed in HIV-1 non-permissive cells,
whereas it is absent from HIV-1-sensitive T-cell lines such
as Jurkat, SupT1, human peripheral blood acute lymphoid
leukemia, and U937 [27]. Since SAMHD1 has not been
studied in CNS cells, our aim in this study was to explore
the role of SAMHD1 in CNS cells. And we found that as-
trocytes and microglia express differential endogenous
levels of SAMHD1, suggesting that possibly the higher level
of SAMHD1 contribute towards HIV restriction in astro-
cytes. Ours is the first study presenting the role of
SAMHD1 in astrocytes.
We found higher reverse transcriptase activity in
microglia compared to astrocytes, suggesting low reverse
transcriptase activity may be responsible for the restric-
tion of HIV infection observed in astrocytes. Our results
also substantiate that decrease in viral replication in as-
trocytes was in correlation with the increased expression
of SAMHD1 and depletion of cellular SAMHD1 in as-
trocytes is sufficient to alleviate the restriction to HIV
infection. This suggests that replication kinetics of the
virus follows an inverse relation with SAMHD1 and con-
firms that SAMHD1 is significantly regulated over the
course of infection in astrocytes. Interestingly, SAMHD1
silencing did not show any significant change in the in-
fection in microglia. Our results support the role of
SAMHD1 as a restriction factor that facilitates in HIV-1
restriction in astrocytes. Since the role of SAMHD1 is to
deplete dNTPs required for RT, we feel that SAMHD1-
mediated repression of HIV-1 replication in astrocyte is
also due to its ability to repress RT. This goes in hand
with the previous reports of SAMHD1 responsible for
suboptimal reverse transcription of viral RNA in T cells
and DCs [25]. However, SAMHD1 may not be the only
restriction factor playing a role in astrocytes. The possi-
bility of additional SAMHD1-dependent/independent
mechanisms cannot be excluded.
Complete eradication of HIV is possible only if
HAART regimens totally stop all new infections of sus-
ceptible cells, along with flushing out existing reservoirs
and blocking formation of additional long-lived viral
reservoirs or reactivating reservoirs in chronically in-
fected patients on HAART [47,48]. To reactivate viral
replication, it is necessary to understand the regulatory
mechanisms involved in establishing persistent reser-
voirs. We found that reactivation of viral replication by
HDAC inhibitor, TSA, is accompanied by decrease in
SAMHD1 expression. This was in contrast to a recent
report showing increase in SAMHD1 expression in
CD4-T cells with TSA exposure [49]. De Silva et al. in-
dicated in their study that HDAC inhibition did not sig-
nificantly change the SAMHD1 protein expression [28].
Though we are not sure the reason for this difference,
this suggests that SAMHD1 may be subjected to post-
transcriptional regulation. Even though, the restricted
HIV-1 replication in myeloid cells, resting T-cells and
macrophages has been linked to SAMHD1 expression,
little is known about its regulatory mechanism. So, in
our next set of experiments, we focused our attention
on the molecular mechanism of SAMHD1 regulation.
The miRNAs induce mRNA cleavage or translation re-
pression by targeting complementary or partly comple-
mentary sequence in the 3′-untranscribed region (UTR)
of target mRNAs [50]. Certain cellular miRNAs have a
physiological role in controlling HIV-1 replication and
in the maintenance of HIV-1 latency in the peripheral
cells [29-31]. We found six miRNAs (miR-124, −150,
−155, −181a-d, −490, and −496) to have binding site on
SAMHD1, suggesting that SAMHD1 may be regulated
by these miRNAs. miR-181 is reported to be very
strongly expressed in the brain [41-43], downregulation
of which contributes to accelerated HIV-associated de-
mentia [51], and miR-155 is reportedly absent from la-
tently infected cells [30]. Hence, we concentrated our
further experiments on these two miRNAs. In our ef-
forts to verify the role of these miRNAs in the regulation
of SAMHD1 and HIV, we saw that modulation of these
miRNAs had an impact on the expression of SAMHD1
and also on HIV-1 replication. Combination of these
two miRNA inhibitors resulted in a substantial increase
in SAMHD1 expression. Interestingly, miR146a (non-
targeting miRNA) inhibition resulted in a slight increase,
which was unexpected. This may be because, miR146a
controls HIV replication through some other means
(other than SAMHD1). The restriction in the astrocytes
was alleviated miRNA overexpression, which was medi-
ated by the change in SAMHD1 expression. Viral miR-
K12-11, an orthologue of cellular miR-155, has been re-
ported to target SAMHD1 [52], which goes in hand with
our finding. To the best of our knowledge, ours is the
first study showing miR181a regulation of SAMHD1 in
astrocytes.
In summary, the importance of our study is that it
provides a proof of concept that SAMHD1 facilitates
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HIV-1 restriction in astrocytes and miR-181a/miR-155
regulates SAMHD1 expression. Overexpression of these
cellular miRNAs or suppression of SAMHD1 removed
the inhibition of HIV-1 replication resulting in increased
viral production from the astrocytes. As a result, this
may allow persistently infected astrocytes to be exposed
to immune surveillance or for the action of HAART. At
this time, this concept is of theoretical nature, as we did
not have any in vivo data. Future in vivo experiments are
needed to evaluate if optimal combinations of miRNA
or SAMHD1 siRNA delivered to astrocytes along with
HAART could reactivate the HIV replication in persist-
ently latent cells.
Material and methods
Cells and reagents
The primary astrocytes (HA #1800) and microglia (HM
#1900) types are isolated from normal human brain and
are commercially available (Sciencell Research Labora-
tories, Carlsbad, CA, USA). Cells were grown in the spe-
cified media as recommended by the manufacturer.
Depending upon the experiments, cells were cultured at
a concentration of 5 × 105 cells/ml in six-well plates (for
transfection experiment) or 1 × 106 cells/ml and allow
them to reach at least 70% confluency before any further
treatment.
HIV infection
Microglia and astrocytes (1 × 106 cells/ml) were infected
with HIV-1Bal, (NIH AIDS Research and Reference
Reagent Program; catalog no. 510) at a concentration
of HIV-1 p24 100 ng/106 cells for 24 h. Cells were
washed to remove unbound virus and replenished
with fresh media.
SAMHD1 mRNA quantification
For SAMHD1 mRNA quantification, total cellular RNA
was extracted using the RNeasy mini kit (Qiagen, Limburg,
the Netherlands) according to the manufacturer’s guide-
lines. One hundred nanograms of the total RNA from each
cell type was used as a template for first-strand cDNA
synthesis using high-capacity reverse transcriptase kit
(Applied Biosystems, Waltham, MA, USA, #4368814).
SAMHD1 mRNA was quantitated by SYBER Green-
based quantitative real-time PCR (Stratagene-3000;
Stratagene, La Jolla, CA, USA) analysis was performed
using the specific primers. Quantification of glyceraldehyde
3-phosphate dehydrogenase (GAPDH) mRNA was carried
out for normalization. Relative expression of mRNA
species was calculated using the comparative CT
method.
Immunoblotting of SAMHD1
To assess SAMHD1 protein levels, cells were harvested
after respective treatments and/or transfection (super-
natant was collected for the detection of p24 and reverse
transcriptase activity assay). Cells were washed twice
with PBS and homogenized in cell lysis buffer (MPER
mammalian protein extraction reagent, Thermo Scien-
tific, Waltham, MA, USA) supplemented with protease
inhibitor mixture (Thermo Scientific, Waltham, MA,
USA) by incubating on ice for 15 min. The homogenates
were centrifuged at 10,000 rpm for 10 min and the
supernatant was used for further analysis. Protein quan-
tification was carried out by using Bio-Rad protein assay
kit (Bio-Rad Laboratories Inc., Hercules, CA, USA).
Thirty micrograms of whole cell lysate was electrophor-
etically separated on an SDS-polyacrylamide gel. Sepa-
rated proteins were transferred to nitrocellulose paper
for 90 min at 100 V, using a wet electroblotting system
(Bio-Rad Laboratories Inc., Hercules, CA, USA). Blots
were blocked for 1 h in 5% non-fat dry milk in Tris-
buffered saline-Tween (TBST) (20 mM Tris, 150 mM
NaCl, 0.1% Tween 20, pH 7.5), followed by incubation
overnight with the primary antibody (1:500 SAMHD1
polyclonal antibody; # sc-86212, Santa Cruz Biotechnol-
ogy, Inc., Dallas, Texas, USA) in 1% milk solution. After
several washes in TBST, the membranes were incubated
in TBST/2% non-fat dry milk, containing the donkey
anti-goat coupled to horse radish peroxidase (1:50,000
dilution; #sc-2020, Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA) for 1 h at RT. After washes in TBST,
immunoreactivity was visualized using Western blotting
detection reagent (SuperSignal West Pico enhancer,
Thermo Scientific, Waltham, MA, USA). Expression of
GAPDH (monoclonal mouse, Sigma-Aldrich, St. Louis,
MO, USA, 1:50,000) was used as loading control.
SAMHD1 siRNA transfection
SAMHD1-siRNA and scrambled siRNA were procured
from Santa Cruz Biotechnology. Astrocytes (2 x 105)
were seeded into antibiotic-free Dulbecco's Modified
Eagle’s medium (DMEM) supplemented with 10% FBS
24 h before transfection. On day of transfection, 75
pmols siRNA duplex and 6 μl of siRNA transfection re-
agent (sc-29528) are diluted into 100 μl serum and
antibiotic-free siRNA transfection medium (sc-36868)
in separate tubes. Both the solutions are mixed gently
and incubated for 30 min at room temperature. This
mixture is diluted with 0.8 ml siRNA transfection
medium, overlayed onto the cells and incubated at 37°C
in a CO2 incubator. After 5 h, cells are supplemented
with 1 ml of normal growth medium containing two
times the normal serum and antibiotics concentration
without removing the transfection mixture. Cells were
left untreated on infected with HIV and incubated for
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another 72 h. A second round of transfection was per-
formed 24 h after the first transfection, whenever it was
needed. Cells were harvested for RNA or protein isola-
tion, and supernatant collected for p24 and RTase
measurements.
miRNA expression assay
Total RNA was isolated using the mir-Vana miRNA isola-
tion (#:1560; Ambion), in accordance with the manufac-
turer’s protocol. RNA concentrations were determined
and 2 ng of each RNA sample were used for cDNA syn-
thesis using TaqMan MicroRNA reverse transcription kit.
Quantitative real-time RT-PCR (qRT-PCR) was performed
using specific primers for miR-155 and miR-181a (Applied
Biosystems, Waltham, MA, USA). All reactions were ana-
lyzed using StepOne Real-Time PCR System (Applied Bio-
systems, Waltham, MA, USA). miRNA levels were
normalized to U6 snRNA control and the cycle threshold
(Ct) values were calculated.
miRNA transfection
Cells in 12-well plates were transfected either with anti-
miR inhibitor or miRNA mimic (Applied Biosystems,
Waltham, MA, USA) in inhibition or in overexpression
experiments respectively, using Lipofectamine according
to the manufacturer’s instructions. Briefly, 5 ul Lipofec-
tamine was added to 200 ml of serum free medium
(DMEM+ F10) per condition for 5 min followed by in-
cubation with anti-miR or miR-mimic at a final concen-
tration of 50 nM. The volume was adjusted to 1 ml with
medium containing 10% FCS and added to the cells. Fol-
lowing transfection, cells were treated with HIV or left
uninfected for 72 h after which the cells were harvested
for RNA or protein isolation, and supernatant collected
for p24 and RTase measurements.
HIV LTR
Following HIV infection/transfection, cells were col-
lected, RNA isolated (RNAeasy mini kit; Qiagen,
Limburg, the Netherlands) and qRT-PCR run to amp-
lify a 180 bp fragment in the LTR-R/U5 region that
represents early stages of reverse transcription of
HIV-1 using the following primers: 5′-primer, 5′-
TCTCTCTGGTTAGACCAGATCTG; 3′-primer, and
5′-ACTGCTAGAGATTTTCCACACTG.
Reverse transcriptase activity
Reverse transcriptase activity of samples was assayed
using a colorimetric reverse transcriptase assay (Roche
Applied Science, Basel, Switzerland). Supernatants were
collected at the end of infection, and the viruses were
pelleted by ultra-centrifugation at 100,000 g for 120 min
at 4°C. Virus pellets were resuspended and lysed by
adding 40 μl lysis buffer, followed by addition of 20 μl
of mixture containing template/primer hybrid and nu-
cleotide, and incubated for 15 h at 37°C. Samples were
then processed as per kit protocol for ELISA and ab-
sorbance read at 405 nm. Reactions were performed in
triplicate, and experiments were performed thrice and
the results averaged.
p24
p24 Ag concentration in the culture supernatants were
assayed in an ELISA method using ZeptoMetrix RETRO-
TEK ELISA kit (ZeptoMetrix Corporation, Buffalo, NY,
USA) as per manufacturer’s recommendations.
TSA treatment
For the TSA (Cell Signaling, Danvers, MA, USA) treat-
ment, after reaching confluency, the cells were with 50
nM TSA for 24 h and washed and proceeded with cell
isolation for RT-PCR and Western blot.
Flow cytometry
Cells (1 × 106) were permeabilized with perm wash
buffer and stained with fluorescein isothiocyanate
(FITC)-conjugated SAMHD1 monoclonal ab (Abcam
plc, Cambridge, MA, USA; #ab128107) at 4°C for
20 min, and washed. Samples were acquired using
FACSCalibur (BD Biosciences, San Jose, CA, USA)
with collection of 100,000 cells and analyzed using
FlowJo software. SAMHD1 ab was conjugated to FITC
by EasyLink FITC Conjugation Kit (Abcam plc, Cambridge,
MA, USA; #ab102885) as per the kit protocol.
Plasmids, transfections, and luciferase assay
The following plasmids were obtained through the NIH
AIDS Reagent Program, Division of AIDS, NIAID, NIH:
pHIV-CAT (cat#2619) from Dr. Gary Nabel and Dr. Neil
Perkins; pSVTat (cat#294) from Dr. Alan Frankel; pNL4-
3-Luc.R−E−(cat#3418) Dr. Nathaniel Landau, Aaron Dia-
mond AIDS Research Center, The Rockefeller University;
and pHEF-VSV-G from Dr. Lung-Ji Chang. Amphoteric
HIV pseudoviruses containing the firefly luciferase gene
were produced by transfecting 293 T cells with pHEF-
VSV-G (10 μg) and pNL4-3. Luc.R-E- (10 μg) in 90-mm
culture dishes. Briefly, plasmid DNA was diluted in
Opti-MEM serum free media (Invitrogen, Carlsbad, CA,
USA). Lipofectamine LTX and PLUS reagent (Invitrogen,
Carlsbad, CA, USA) diluted in equal volume and added
to diluted DNA at a 1:1 ratio. Mixture was incubated for
5 min to allow formation of DNA-liposome complexes.
Culture supernatants containing the pseudoviruses were
collected 72 h post-transfection and clarified by centrifu-
gation at 400 g. Pseudoviruses were competent for single
round of replication. Astrocytes infected with the HIV-
luciferase pseudovirus (20 ng) were harvested 3 dpi,
washed with PBS and lysed. Lysates were pre-cleared by
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centrifugation at 12,000 g for 2 min at 4°C. Luciferase
concentration in whole cell lysates from cells was deter-
mined using a Luciferase assay system (Promega, Madison,
WI, USA), according to the manufacturer’s instructions
(Technical Bulletin #TB281). One hundred microliters of
luciferase assay reagent were dispensed in a 96-well mi-
croplate (Costar, Corning, NY), 20 μl of cell lysate added
to each well, mixed by pipetting, and read on a lumin-
ometer (Synergy HT, BioHIT, Sartorius AG, Goettingen,
Germany).
Statistical analysis
Results are presented as mean ± SE of three independent
experiments. Differences between treated and untreated
cultures were compared by Student’s t-test. Comparisons
of more than two groups were made using analysis of
variance (ANOVA) (Kruskal-Wallis). Data were analyzed
using Graphpad Prism version 5.0 software and statis-
tical significance considered when P value ≤0.05.
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